MCID: PNC103
MIFTS: 31

Pancreatic Cancer 4

Categories: Genetic diseases, Endocrine diseases, Cancer diseases, Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Pancreatic Cancer 4

MalaCards integrated aliases for Pancreatic Cancer 4:

Name: Pancreatic Cancer 4 54 71 29
Pancreatic Cancer, Susceptibility to, 4 13
Pnca4 71

Classifications:



External Ids:

OMIM 54 614320
MeSH 42 D010190

Summaries for Pancreatic Cancer 4

UniProtKB/Swiss-Prot : 71 Pancreatic cancer 4: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

MalaCards based summary : Pancreatic Cancer 4, also known as pancreatic cancer, susceptibility to, 4, is related to pancreatic cancer susceptibility 4 and pancreatic cancer. An important gene associated with Pancreatic Cancer 4 is BRCA1 (BRCA1, DNA Repair Associated). The drugs Pancrelipase and Secretin have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and t cells.

Description from OMIM: 614320

Related Diseases for Pancreatic Cancer 4

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer 4 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 pancreatic cancer susceptibility 4 10.8
2 pancreatic cancer 9.8
3 pancreatitis 9.8
4 adenocarcinoma 9.6

Symptoms & Phenotypes for Pancreatic Cancer 4

Clinical features from OMIM:

614320

Drugs & Therapeutics for Pancreatic Cancer 4

Drugs for Pancreatic Cancer 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 421)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53608-75-6
2
Secretin Approved, Investigational Phase 4 108153-74-8
3
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 61825-94-3 5310940 9887054 43805 6857599
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
6
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Iron Approved Phase 4 7439-89-6 23925
9
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
10
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 772 46507594
11
Ethanol Approved Phase 4,Phase 2,Phase 3 64-17-5 702
12
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
13
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
14
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
15
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
16
Nicotine Approved Phase 4 54-11-5 942 89594
17
Etomidate Approved Phase 4 33125-97-2 36339 667484
18
Meperidine Approved Phase 4 57-42-1 4058
19
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
20
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
21
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
22
Sunitinib Approved, Investigational Phase 4,Phase 2 341031-54-7, 557795-19-4 5329102
23
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 1 169590-42-5 2662
24
Thrombin Approved Phase 4
25
Desflurane Approved Phase 4 57041-67-5 42113
26
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
27
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
28
Tegafur Approved Phase 4,Phase 2 17902-23-7 5386
29
Somatostatin Approved Phase 4,Phase 2 38916-34-6, 51110-01-1 53481605
30
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
31
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
32
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
33
Butyric Acid Experimental Phase 4 107-92-6 264
34 pancreatin Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
40 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
42 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
44 Analgesics Phase 4,Phase 2,Phase 1
45 Anesthetics Phase 4,Phase 3
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Adjuvants, Anesthesia Phase 4
48 Analgesics, Opioid Phase 4,Phase 1
49 Anesthetics, General Phase 4
50 Anesthetics, Intravenous Phase 4

Interventional clinical trials:

(show top 50) (show all 642)

id Name Status NCT ID Phase Drugs
1 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
2 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
3 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
4 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
5 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
6 Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study Unknown status NCT01737463 Phase 4
7 Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer Completed NCT01346410 Phase 4
8 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
9 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
10 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
11 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
12 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
13 Prospective Study of Celiac Block Injection: 1 vs. 2 Completed NCT00583479 Phase 4
14 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
15 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
16 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
17 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
18 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
19 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
20 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
21 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
22 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
23 The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
24 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
25 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
26 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
27 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4 Desflurane
28 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
29 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
30 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
31 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
32 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Active, not recruiting NCT02238847 Phase 4
33 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
34 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
35 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
36 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Not yet recruiting NCT02570529 Phase 4 Albis®;Placebo
37 Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Not yet recruiting NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
38 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Not yet recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
39 A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
40 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
41 Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer Terminated NCT01887041 Phase 4
42 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
43 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
44 Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas Unknown status NCT02311439 Phase 2, Phase 3 FOLFIRINOX + CRT
45 Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer Unknown status NCT00813696 Phase 3 gemcitabine;cisplatin
46 Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
47 A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
48 Hyperthermia European Adjuvant Trial Unknown status NCT01077427 Phase 3 Gemcitabine
49 Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma Completed NCT00044031 Phase 3
50 Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer Completed NCT00005648 Phase 3 Gemcitabine with R115777;Gemcitabine with Placebo

Search NIH Clinical Center for Pancreatic Cancer 4

Genetic Tests for Pancreatic Cancer 4

Genetic tests related to Pancreatic Cancer 4:

id Genetic test Affiliating Genes
1 Pancreatic Cancer 4 29

Anatomical Context for Pancreatic Cancer 4

MalaCards organs/tissues related to Pancreatic Cancer 4:

39
Pancreas, Lung, T Cells, Liver, Testes, Prostate, Colon

Publications for Pancreatic Cancer 4

Articles related to Pancreatic Cancer 4:

id Title Authors Year
1
Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma. ( 26419361 )
2015
2
Usefulness of diffusion-weighted imaging (DWI) for the detection of pancreatic cancer: 4 case reports. ( 18507125 )
2008

Variations for Pancreatic Cancer 4

ClinVar genetic disease variations for Pancreatic Cancer 4:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 BRCA1 NM_007294.3(BRCA1): c.68_69delAG (p.Glu23Valfs) deletion Pathogenic rs80357783 GRCh37 Chromosome 17, 41276047: 41276048

Expression for Pancreatic Cancer 4

Search GEO for disease gene expression data for Pancreatic Cancer 4.

Pathways for Pancreatic Cancer 4

GO Terms for Pancreatic Cancer 4

Sources for Pancreatic Cancer 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....